

approximately 30 hours to complete per response, for a total of 60 burden hours. Thus, the total burden for this collection is estimated to be 120 hours.

FDA has adjusted its burden estimate, which has resulted in a decrease of 60 hours and 2 respondents to the currently approved burden. This adjusted burden estimate is based on historical trends for smokeless tobacco warning plans. As of this OMB submission, FDA has received a total of 47 original smokeless warning plans, and a total of 33 supplements. Generally, after receiving the initial influx of original smokeless warnings plans, the number of annual warning plan submissions has decreased, and FDA does not expect submissions to increase at this time. Since publication of the 60-day notice, we removed the cigar warning plan burden from this collection.

**Brian Fahey,**

*Associate Commissioner for Legislation.*

[FR Doc. 2026-00792 Filed 1-15-26; 8:45 am]

**BILLING CODE 4164-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Cancer Institute.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocast at the following link: <http://videocast.nih.gov/>.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, National Cancer Institute.

*Date:* March 9-10, 2026.

*Open:* March 09, 2026, 10:00 a.m. to 10:30 a.m.

*Agenda:* Call to Order and the Opening Remarks.

*Closed:* March 09, 2026, 11:00 a.m. to 4:00 p.m. March 10, 2026, 10:10 a.m. to 3:00 p.m.

*Agenda:* Personnel qualifications and performance, and competence of individual investigators.

*Address:* National Institutes of Health, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850, Virtual Meeting.

*Contact Person:* Mehrdad M. Tondravi, Ph.D., Chief Institute Review Office, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 2W-464 MSC 9711, Rockville, MD 20852, 240-276-5664, [tondravim@mail.nih.gov](mailto:tondravim@mail.nih.gov).

Information is also available on the Institute's/Center's home page: <https://deainfo.nci.nih.gov/advisory/bsc/index.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.396, Cancer Biology Research, National Institutes of Health, HHS)

**Zieta M. Charles,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-00821 Filed 1-15-26; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Training: Midcareer Investigator Award in Patient-Oriented Research.

*Date:* February 10, 2026.

*Time:* 12:00 p.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Erica Charlott Spears, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-3211, [spearsec@csr.nih.gov](mailto:spearsec@csr.nih.gov).

*Name of Committee:* Musculoskeletal, Oral and Skin Sciences Integrated Review Group; Musculoskeletal Rehabilitation Sciences Study Section.

*Date:* February 19, 2026.

*Time:* 9:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Richard Michael Lovering, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1000J, Bethesda, MD 20892, (301) 867-5309, [loveringrm@mail.nih.gov](mailto:loveringrm@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 13, 2026.

**Rosalind M. Niamke,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-00785 Filed 1-15-26; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse; Notice of Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be held as a virtual meeting and is open to the public, as indicated below. Individuals who plan to view the virtual meeting and need special assistance such as sign language interpretation or other reasonable accommodations to view the meeting, should notify Dr. Gillian Acca via email at [gillian.acca@nih.gov](mailto:gillian.acca@nih.gov) ten days in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov/>).

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Drug Abuse.

*Date:* February 3, 2026.

*Closed:* 10:30 a.m. to 11:45 a.m.

*Agenda:* To review and evaluate grant applications.

*Open:* 1:00 p.m. to 5:00 p.m.

*Agenda:* Presentations and other business of the Council.

*Meeting Format:* Virtual Meeting.

*Place:* National Institutes of Health, National Institute on Drug Abuse, Three White Flint North, 11601 Landsdown Street, Bethesda, MD 20852.

*Contact Person:* Susan R.B. Weiss, Ph.D., Director Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown Street, Bethesda, MD 20852, 301-443-6480, [sweiss@nida.nih.gov](mailto:sweiss@nida.nih.gov).

*Contact Person:* Gillian Acca, Ph.D., Health Scientist Administrator, Division of Extramural Research, Office of Extramural Policy, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09C70, 11601 Landsdown Street, Bethesda, MD 20852, 301-827-5863, [gillian.acca@nih.gov](mailto:gillian.acca@nih.gov).

The meeting identified below has been scheduled in the event the Council is unable to complete all agenda items identified for the February 3, 2026, meeting. Information on the agenda items and/or the necessity to hold the meeting listed below will be posted on the Institute/Center homepage (link identified below).

*Name of Committee:* National Advisory Council on Drug Abuse.

*Date:* March 9, 2026.

*Closed:* 10:30 a.m. to 11:45 a.m.

*Agenda:* To review and evaluate grant applications not completed at the February meeting.

*Open:* 1:00 p.m. to 5:00 p.m.

*Agenda:* Presentations and other business of the Council not completed at the February meeting.

*Meeting Format:* Virtual Meeting.

*Place:* National Institutes of Health, National Institute on Drug Abuse, Three White Flint North, 11601 Landsdown Street, Bethesda, MD 20852.

*Contact Person:* Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown Street, Bethesda, MD 20852, 301-443-6480, [sweiss@nida.nih.gov](mailto:sweiss@nida.nih.gov).

*Contact Person:* Gillian Acca, Ph.D., Health Scientist Administrator, Division of Extramural Research, Office of Extramural Policy, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09C70, 11601 Landsdown Street, Bethesda, MD 20852, 301-827-5863, [gillian.acca@nih.gov](mailto:gillian.acca@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to Dr. Gillian Acca via email at [gillian.acca@nih.gov](mailto:gillian.acca@nih.gov). The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: [www.drugabuse.gov/NACDA/NACDAHome.html](http://www.drugabuse.gov/NACDA/NACDAHome.html), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

**Zieta M. Charles,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-00820 Filed 1-15-26; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Special topics in Social and Community Influences Across the Life course.

*Date:* January 28, 2026.

*Time:* 10:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Rochelle Francine Hentges, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1000C, Bethesda, MD 20892, (301) 402-8720, [hentgesrf@mail.nih.gov](mailto:hentgesrf@mail.nih.gov).

This notice is being published less than 15 days from the meeting date due to exceptional circumstances. As a result of the 43-day government shutdown, due to lapsed appropriations, the above meeting was canceled. This meeting was to assess the scientific and technical merit of NIH grant applications, required by statute to disburse NIH funds. The meeting must take place urgently so that evaluations of biomedical research applications addressing multiple major public health priorities can be submitted to the national advisory councils for timely funding recommendations.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: January 14, 2026.

**Bruce A. George,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-00845 Filed 1-15-26; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-7106-N-12]

### Privacy Act of 1974; System of Records

**AGENCY:** Department of Housing and Urban Development (HUD).

**ACTION:** Notice of a modified systems of records.

**SUMMARY:** Under the Privacy Act of 1974, as amended, the Department of Housing and Urban Development (HUD) is issuing a public notice of its intent to modify the HUD System of Records Notices for the HUD systems of records listed below.

**DATES:** Comments will be accepted on or before February 17, 2026. This proposed action will be effective on the date following the end of the comment period unless comments are received which result in a contrary determination.

**ADDRESSES:** You may submit comments, identified by docket number by one method:

*Federal e-Rulemaking Portal:* <http://www.regulations.gov>. Follow the instructions provided on that site to submit comments electronically.

*Fax:* 202-485-9531.

*Email:* [privacy@hud.gov](mailto:privacy@hud.gov).

*Mail:* Attention: Privacy Office; Shalanda Capehart, Acting Chief Privacy Officer; The Executive Secretariat; 451 7th Street SW, Room 10139; Washington, DC 20410-0001.

*Instructions:* All submissions received must include the agency name and